Kaposi sarcoma associated with rituximab-based cytotoxic therapy

J Oncol Pharm Pract. 2020 Jan;26(1):220-223. doi: 10.1177/1078155219835592. Epub 2019 Mar 9.

Abstract

Kaposi sarcoma (KS) is a low-grade mesenchymal angioproliferative disease, mostly observed in immune compromised patients. KS is mostly encountered in HIV-positive or organ transplant patients. The drugs causing immunosuppression have also been associated with KS. Here, we present a KS experience associated with rituximab-based therapy.

Keywords: HHV-8; Kaposi sarcoma; Rituximab; lymphoma.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents, Immunological / adverse effects*
  • Humans
  • Male
  • Rituximab / adverse effects*
  • Sarcoma, Kaposi / chemically induced*

Substances

  • Antineoplastic Agents, Immunological
  • Rituximab